A company called Biogen Idec has decided to discontinue work on an experimental drug that was designed to treat Lou Gehrig’s disease (which is also called A.L.S.). The drug failed to work in a late stage clinical trial. There is another company that is continuing to work on a different drug for the disease. Lou Gehrig’s disease is also called amyotrophic lateral sclerosis. This long, multi-syllabic, name is often shortened to A. L. S. when it is discussed. It is a progressive neurodegenerative disease that affects nerve cells in the brain and in the spinal cord. According to the ALS … Continue reading →